The Efficacy and Safety of Cyclosporin A in Pregnant Patients with Systemic Autoimmune Diseases

Abstract

We found no evidence justifying the suspension of CYS A when a pregnancy occurs. The drug does not appear to promote maternal-fetal complications and should be continued in patients who benefit from therapy. Data regarding breast-feeding during therapy are still scarce, but no evidence of toxicity has emerged.